347 related articles for article (PubMed ID: 32100934)
41. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S; Matei DE; Konstantinopoulos PA; Wang BX; Gadalla R; Block MS; Jewell A; Gaillard SL; McHale M; McCourt C; Temkin S; Girda E; Backes FJ; Werner TL; Duska L; Kehoe S; Colombo I; Wang L; Li X; Wildman R; Soleimani S; Lien S; Wright J; Pugh T; Ohashi PS; Brooks DG; Fleming GF
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288469
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Ho WJ; Zhu Q; Durham J; Popovic A; Xavier S; Leatherman J; Mohan A; Mo G; Zhang S; Gross N; Charmsaz S; Lin D; Quong D; Wilt B; Kamel IR; Weiss M; Philosophe B; Burkhart R; Burns WR; Shubert C; Ejaz A; He J; Deshpande A; Danilova L; Stein-O'Brien G; Sugar EA; Laheru DA; Anders RA; Fertig EJ; Jaffee EM; Yarchoan M
Nat Cancer; 2021 Sep; 2(9):891-903. PubMed ID: 34796337
[TBL] [Abstract][Full Text] [Related]
43. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma.
Parikh ND; Marshall A; Betts KA; Song J; Zhao J; Yuan M; Wu A; Huff KD; Kim R
J Comp Eff Res; 2021 Apr; 10(5):343-352. PubMed ID: 33442996
[No Abstract] [Full Text] [Related]
44. The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.
Liu C; Zhu S; Dong Y; Shao J; Liu B; Shen J
Front Immunol; 2022; 13():930096. PubMed ID: 35874743
[TBL] [Abstract][Full Text] [Related]
45. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
46. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
Deeks ED
Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
[TBL] [Abstract][Full Text] [Related]
47. Recurrent cervical cancer with PD-L1 amplification treated with nivolumab: A case enrolled in the BELIEVE trial.
Yoshimoto D; Taguchi A; Tanikawa M; Sone K; Shimoi T; Tsuruga T; Oda K; Osuga Y
J Obstet Gynaecol Res; 2022 Jul; 48(7):2010-2014. PubMed ID: 35373441
[TBL] [Abstract][Full Text] [Related]
48. Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
[No Abstract] [Full Text] [Related]
49. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.
Pinato DJ; Cortellini A; Sukumaran A; Cole T; Pai M; Habib N; Spalding D; Sodergren MH; Martinez M; Dhillon T; Tait P; Thomas R; Ward C; Kocher H; Yip V; Slater S; Sharma R
BMC Cancer; 2021 Mar; 21(1):301. PubMed ID: 33757459
[TBL] [Abstract][Full Text] [Related]
50. Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
[TBL] [Abstract][Full Text] [Related]
51. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
52. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
53. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract][Full Text] [Related]
54. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
[TBL] [Abstract][Full Text] [Related]
55. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Yau T; Hsu C; Kim TY; Choo SP; Kang YK; Hou MM; Numata K; Yeo W; Chopra A; Ikeda M; Kuromatsu R; Moriguchi M; Chao Y; Zhao H; Anderson J; Cruz CD; Kudo M
J Hepatol; 2019 Sep; 71(3):543-552. PubMed ID: 31176752
[TBL] [Abstract][Full Text] [Related]
56. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
Front Oncol; 2018; 8():269. PubMed ID: 30057891
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
[TBL] [Abstract][Full Text] [Related]
58. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
59. Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations.
Reiter FP; Rau M; Kunzmann V; Kickuth R; Klein I; Neumann O; Stenzinger A; Schirmacher P; Geier A
Z Gastroenterol; 2023 Jan; 61(1):71-75. PubMed ID: 36379463
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
